Healthcare / Medical Care FacilitiesIstanbul
$19.80
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-37.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.9B
P/E
1980.0x
↑EV/EBITDA
47.8x
↑ROE
0.1%
↓Gross Margin
16.2%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+39.2%
FCF CAGR
—
FCF margin
-2.8%
FCF / Net income
-14.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.35B · net income $2.7M · FCF $-37.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.35B | $1.35B | $1.32B | $890.8M | $498.9M |
| Net Income | $2.7M | $2.7M | $-30.2M | $132.5M | $-146.4M |
| EBITDA | $205.3M | $205.3M | $168.1M | $286.0M | $-47.5M |
| EPS | 0.01 | 0.01 | -0.06 | 0.27 | -0.29 |
| Gross Margin | 16.2% | 16.2% | 22.9% | 28.0% | 15.8% |
| Operating Margin | 4.9% | 4.9% | -1.5% | 3.3% | -4.9% |
| Net Margin | 0.2% | 0.2% | -2.3% | 14.9% | -29.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.05 | 0.11 | 0.20 |
| Current Ratio | 1.76 | 1.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-37.7M | $-37.7M | $134.4M | $-46.8M | $-120.8M |
| Returns | |||||
| ROE | 0.1% | 0.1% | -1.7% | 9.3% | -16.4% |
| Valuation | |||||
| P/E | 1980.00 | 1980.00 | — | 17.48 | — |
| EV/EBITDA | 47.81 | 47.81 | 17.93 | 8.37 | — |
| P/B | 5.19 | 5.19 | 1.71 | 1.63 | 2.41 |
| Growth & Yield | |||||
| Revenue Growth | 1.9% | 1.9% | 48.3% | 78.5% | — |
| EPS Growth | 108.8% | 108.8% | -122.8% | 190.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
592.1%
EPS terminal req.
$1.76
Spread vs growth
-483.3%
5Y implied EPS CAGR
231.6%
EPS terminal req.
$2.13
Spread vs growth
-122.8%
10Y implied EPS CAGR
91.0%
EPS terminal req.
$3.42
Spread vs growth
17.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+200.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → 0.01
Residual
+200.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.